SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

Search

Valneva SE

Atidarymo kaina

3.23 2.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.1

Max

3.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

-37M

Pardavimai

7.1M

53M

Pelnas, tenkantis vienai akcijai

-0.25

Pelno marža

-69.865

Darbuotojai

713

EBITDA

-19M

-26M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+84.47% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-64M

513M

Ankstesnė atidarymo kaina

0.69

Ankstesnė uždarymo kaina

3.23

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Valneva SE Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-11-15 10:28; UTC

Pagrindinės rinkos jėgos

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

2024-09-03 10:28; UTC

Uždarbis

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

2024-11-15 10:34; UTC

Rinkos pokalbiai

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

2024-09-03 10:31; UTC

Rinkos pokalbiai

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Akcijų palyginimas

Kainos pokytis

Valneva SE Prognozė

Kainos tikslas

By TipRanks

84.47% į viršų

12 mėnesių prognozė

Vidutinis 5.7 EUR  84.47%

Aukščiausias 8.1 EUR

Žemiausias 3.3 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Valneva SE kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.182 / 3.32Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.